key: cord-0921319-9jnfj67c
authors: Abbas, Rawad; El Naamani, Kareem; Sweid, Ahmad; Schaefer, Joseph W.; Bekelis, Kimon; Sourour, Nader; Elhorany, Mahmoud; Pandey, Aditya S.; Tjoumakaris, Stavropoula; Gooch, Michael R.; Herial, Nabeel A.; Rosenwasser, Robert H.; Jabbour, Pascal
title: Intracranial Hemorrhage in COVID-19 patients: A Case Series
date: 2021-07-21
journal: World Neurosurg
DOI: 10.1016/j.wneu.2021.07.067
sha: 5830086559a86cbf908d55254649d24f430f3fca
doc_id: 921319
cord_uid: 9jnfj67c

Background The COVID-19 pandemic is an ongoing public health emergency. While most cases end in asymptomatic or minor illness, there is growing evidence that some COVID-19 infections result in non-conventional dire consequences. Objective To describe the characteristics of intracranial hemorrhage (ICH) patients who were infected with SARS-CoV-2. Also, with the existing literature, we raise the idea of a possible association between SARS-CoV-2 infection and ICH and propose possible pathophysiological mechanisms connecting the two. Methods We retrospectively collected and analyzed intracranial hemorrhage cases who were also positive for SARS-CoV-2 from four tertiary-care cerebrovascular centers. Results We identified a total of nineteen patients consisting of eleven males (58%) and eight females (42%). Mean age was 52.2 with 95% being less than 75 years of age. With respect to COVID-19 illness, 50% had mild-moderate disease, 21% had severe disease, and 20% had critical disease requiring intubation. Of the nineteen cases, twelve patients had intraparenchymal hemorrhage (63%), six had subarachnoid hemorrhage (32%), and one patient had a subdural hematoma (5%). Intracerebral hemorrhage score of 0 – 2 were in 43% and 3 – 6 in 57%. Modified Rankin Scale cores at discharge were 0-2 in 23% and 3-6 in 77%. The mortality rate was 59%. Conclusion Our series shed light on a distinct pattern of intracerebral hemorrhage in COVID-19 positive cases compared to typical non-COVID cases, namely the severity of hemorrhage, high mortality rate, and the young age of patients. Further research is warranted to delineate a potential association between SARS-CoV-2 infection and intracranial hemorrhage.

hypercoagulable states and acute ischemic stroke 3-7 , that of COVID-19 and Intracranial 45 hemorrhage is much less well-described with few studies being published thus far 5, [8] [9] [10] . Infected 46 patients may present with ICH or develop ICH during the course of their hospitalization, often 47 with debilitating consequences 11 . In this paper, we aim to highlight the clinical, radiological, and 48 laboratory characteristics, as well as functional outcomes of COVID-19 patients who either 49 presented with ICH or subsequently developed ICH in the course of their illness. In this retrospective case series, data were collected from four tertiary care, high-volume 54 cerebrovascular centers for nineteen patients from March through December of 2020. The 55 diagnosis of SARS-CoV-2 infection was made based on RT-qPCR testing of a nasal swab 56 sample from each patient. Patients with a positive test at admission or up to 28 days prior and 57 who presented with ICH, or subsequently developed ICH during their hospital course, were 58 included. 28 days is an arbitrary number agreed upon by the authors to try to establish a potential 59 timeline between COVID-19 and ICH. Patients who tested negative twice for COVID-19 and 60 patients who tested positive more than 28 days prior to admission were excluded. The study 61

protocol was reviewed and approved by the Institutional Review Board. Patients' consent was 62 not obtained due to the retrospective nature of the study. The following data were collected from 63 J o u r n a l P r e -p r o o f each patient's electronic medical record: age, sex, history of hypertension, history of 64 hyperlipidemia, history of chronic heart, lung, kidney, or liver disease, history of diabetes, 65 history of atrial fibrillation, history of anticoagulant/antiplatelet use, smoking status, COVID-19 66 symptoms, ICH data, laboratory data, management, length of stay, discharge location and 67 modified Rankin Scale (mRS) at discharge. Microsoft excel was used to run descriptive analyses 68 of the data. To preserve patient anonymity and in compliance with Institutional Review Board 69 regulations, we do not present the full data for individual cases and instead report the aggregated 70 data or individual deidentified data points. in this series, eight of whom were females (42.1%) and eleven (57.9%) were males. The mean 78 age of patients was 52.6  15.8 years (range: 24 -85 years) Fourteen patients (73.7%) were less 79 than 60 years of age. The most common comorbidities were hypertension (52.6%), chronic heart 80 disease (31.6%), and diabetes (21.1%). Other notable comorbidities were hyperlipidemia 81 (21.1%), chronic kidney disease (15.8%), and atrial fibrillation (15.8%). One patient (5.3%) had 82 chronic lung disease and one patient (5.3%) was a current smoker. Five patients (26.3%) did not 83 have any comorbidities or past medical history. In addition, four patients (21.1%) were on 84 anticoagulation (three patients were on heparin; one patient was on a drip, another two were 85 taking 2500 and 5000 units subcutaneously every 12 hours and 8 hours respectively, and the 86 fourth patient was on warfarin daily) and two patients (10.5%) were on antiplatelets. 87 Additionally, none of the patients were on steroids. 68.4% had a favorable preadmission mRS of 88 and a Hunt and Hess grade  SAH and three patients (75%) had a Hunt and Hess grade V 113 SAH, one of whom ruptured the aneurysm during a protracted coughing episode. Out of 114 available data from our institution, one aneurysm was a fusiform aneurysm of the distal posterior 115 inferior cerebellar artery, and one was a blister aneurysm of the anterior choroidal artery. One 116 patient had severe diffuse SAH on computed tomography angiography scan (CTA) and the 117 aneurysm was not visualized. The patient then passed away soon after presentation and no 118 further workup was done. From the patients who presented with IPH at our institution, two of the 119 intraparenchymal hemorrhages were in the left and right frontal lobes with intraventricular 120 extension, two were in the bilateral thalamic area, one was in the right parietal lobe, one in the 121 left occipital lobe, and one in the left cerebellar hemisphere with extension into the 4 th ventricle. 122

All hemorrhages were of arterial origin. The mean IPH volume was 45.9  66.7 cm 3 and the 123 largest IPH diameter was 51.8  37.5 mm. Moreover, unfavorable ICH scores (3-6) were 124 documented in 57.2% of patients (table 4) . 125 J o u r n a l P r e -p r o o f

Two patients (13.3%) received a decompressive hemicraniectomy, three (20%) underwent 129 aneurysm embolization (one patient succumbed to irreversible neurological damage and passed 130 away), and ten (66.7%) had supportive management. Six patients (31.6%) had complications 131 during their hospital course; one patient with SAH (brain death), and five patients with IPH. Of 132 these five patients, one developed brain death, two developed herniation, and one patient had 133 refractory increased intracranial pressure and ventricular tachycardia. The mean length of 134 hospital stay was 5.1  6.5 days. Interestingly, unfavorable mRS scores at discharge (3-6) were 135 in 76.5%, and the mortality rate was 58.8%. Of the patients who passed away 60% and 90% 136 were less than 60 and 75 years of age respectively (table 5) . 137

Discussion 139 140 A little over a year into the pandemic and the medical community is still reporting novel 141 and unexpected sequelae resulting from the SARS-CoV-2/COVID-19 infection. [12] [13] [14] Published 142 studies on ICH in COVID-19 patients are minimal and, in this series, we highlight potential 143 disparities from established characteristics of ICH patients. 5,8,10,11,15 144 In this case series, the mean age at presentation was 52.6 years old with 74% of patients 145 being less than 60 years of age and 95% were less than 75 years of age. This is much younger 146 than expected; many prospective cohort studies and meta-analyses on ICH report mean ages of 147 patients at presentation ranging from 68 -75 years. [16] [17] [18] In addition, over a period of 28 years, 148

van Asch CJ, Ja Luitse M, Je Rinkel G, van der Tweel I, Algra A, and Klijn CJ found the 149 incidence of ICH in patients less than 60 years of age to be 0. In our cohort, the majority of patients were male (58%), which is again reflected in recently 155 published series whereby male patients comprised 60% -100% of the study population. 5,15,21 156

Moreover, male gender is a well-established risk factor for ICH, therefore, this is in accordance 157 with current literature. 22,23 158

The most prevalent vascular comorbidities were hypertension (HTN) and chronic heart 159 disease (CHD) which have been reported in most studies on ICH in COVID-19 patients. trend was also observed in various other studies and reports. 11, 15, 21, 28 Hence, it appears that the 171 pathophysiology behind these hemorrhages differs from what has already been established for 172 non-COVID-19 related spontaneous ICH. 173

Anticoagulation in the setting of COVID-19 is not a straightforward process and should 174 balance the hypercoagulable state brought upon by COVID-19. In our series, four patients were 175 receiving therapeutic as well as prophylactic anticoagulation. Specifically, one patient was 176 placed on a heparin drip for a deep venous thrombosis, and subsequently developed a large right 177 frontal IPH with intraventricular extension and passed away. This may introduce a trend that 178 heparinization in the setting of COVID-19 may lead to ICH. One case report reported that a 42-179

year-old hospitalized for COVID-related ARDS developed large bilateral ICH after initiating a 180 heparin drip. 29 Moreover, a recent retrospective study found that most intracerebral hemorrhages 181 in COVID-19 occurred in the setting of therapeutic anticoagulation and was associated with 182 Therefore, it is reasonable to conclude that the increase in D-dimer levels stemming from SARS-205

CoV-2 add to the risk of ICH. 206

Two patients in our series developed spontaneous non-aneurysmal SAH. The exact 207 mechanism of this occurrence has yet to be fully understood. One recent case series reported one 208 incidental aneurysm out of 4 patients with SAH and therefore introduced spontaneous SAH as a 209 severe neurologic manifestation of COVID-19 and postulated the hyperinflammatory state in the 210 setting of COVID-19 as a potential mechanism. 46 Similarly, a recent review hypothesized that 211 hypercytokinemia and inflammation may contribute to vascular degeneration leading to 212 aneurysm formation and size/morphology change, therefore resulting in rupture and SAH. 47 213

It is noteworthy to mention that in this series unfavorable ICH scores (3 -6) were recorded 214 in 57% of IPHs when reported, and poor outcome (mRS 3 -6) in 77% with a mortality rate 215 (mRS 6) of 59%. Also, six of ten patients who passed away were below the age of 60. These 216 findings deviate from existing literature on spontaneous ICH. A recent, comprehensive 217 systematic review and meta-analysis of thirty population-based studies reported mortality rates 218 J o u r n a l P r e -p r o o f of 36.3% at one month, 35.3% at three months, and 50.7% at one year, all of which are all less 219 than in our series. 19 In addition, multiple studies have robustly established older age as an 220 independent predictor of short and long-term mortality, and that case fatality declines in patients 221 younger than 75 years old. 18,48-50 For a small series, it is intriguing that 90% of deaths occurred in 222 patients less than 75 years of age. In fact, in the overwhelming majority of studies reporting on 223 COVID-19 and ICH, the mortality rate ranged from 42% to 100%. 15 One postulation is that 224 consistently elevated CRP levels, given the active inflammation from SARS-CoV-2, impair 225

proper healing, and thus portend higher mortality and poor functional outcome. 51 Another 226 postulation is that impaired autoregulation and disruption of the signaling cascade initiated by 227 ACE-2 would lead to greater hemorrhage volume, which is independently associated with 228 increased mortality. 52 However, the precise pathophysiology is likely multifactorial and still 229 poorly understood. Further investigation is warranted. 230

beyond the scope of this study to establish a causal relationship between SARS-CoV-2 infection 232 and ICH. Nevertheless, the trends identified in this study should raise concern about the unusual 233 features of ICH in this subset of patients and should be the focus of future investigation. 234 235

Our study aims to shed light over a potential association between COVID-19 and ICH. However, 237 our study has some limitations that are worth mentioning. First, it is a retrospective case series, 238 with a small sample size. Thus, data interpretation cannot establish a causal relationship between 239 specific type of bleeds and COVID-19. A larger sample size in a prospective study design would 240 better contribute to further understanding of the cause of hemorrhage and improve 241 generalizability of our results. Additionally, the heterogeneous collection of intraparenchymal, 242 SAH, and subdural hematomas together make the interpretation harder, especially when both the 243 infratentorial and supratentorial hemorrhages are included as well. Furthermore, many patients 244 were in critical condition on presentation and passed away soon thereafter and CTA scans were 245 not performed for every patient potentially masking an underlying vascular pathology. Finally, 246 CNS biopsies were not available at the point of data acquisition. In this case series, we report nineteen ICH cases in SARS-CoV-2 positive patients. These 250 cases add to and support the existing pool of evidence on the distinctly different characteristics 251 of ICH in COVID-19 patients. In addition, they shed light on unique features, predominantly 252 young age, severe hemorrhage, and markedly high mortality, especially in the younger age 253 group, and should therefore raise questions about a likely association between SARS-CoV-2 254 1 (5.9) 2 1 (5.9) 3 2 (11.8) 4 0 (0) 5 1 (5.9) 6 10 (58.8) Mortality Age <60 Age 60-75 Age >75 10 (58.8) 6 (60) 3 (30) 1 (10) ACE-2 = angiotensin converting enzyme -2 ARDS = acute respiratory distress syndrome CHD = chronic heart disease CNS = central nervous system COVID-19 = corona virus disease 2019 CRP = C-reactive protein HTN = hypertension ICH = intracranial hemorrhage IPH = intraparenchymal hematoma LVO = large vessel occlusion mRS = modified Rankin Scale RAAS = renin-angiotensin-aldosterone-system SAH = subarachnoid hemorrhage

Cerebral ischemic and hemorrhagic complications 290 of coronavirus disease 2019

Risk factors for intracerebral hemorrhage in the 292 general population: a systematic review

Epidemiology, Risk Factors, and Clinical Features of 294 Intracerebral Hemorrhage: An Update

Time trends in incidence, case 296 fatality, and mortality of intracerebral hemorrhage

Incidence, case 300 fatality, and functional outcome of intracerebral haemorrhage over time, according to 301 age, sex, and ethnic origin: a systematic review and meta-analysis

Intracerebral haemorrhage and COVID-19: 304 Clinical characteristics from a case series

Clinical and Imaging Characteristics in Patients 307 with SARS-CoV-2 Infection and Acute Intracranial Hemorrhage

Risk 309 factors for intracerebral hemorrhage in a pooled prospective study

Blood 312 pressure in relation to the incidence of cerebral infarction and intracerebral 313 hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant

Risk factors for intracerebral hemorrhage 316 differ according to hemorrhage location

Is hypertension a more frequent risk factor for deep than for 318 lobar supratentorial intracerebral haemorrhage?

Update in intracerebral hemorrhage

SARS-CoV-2: Structure, Biology, 323 and Structure-Based Therapeutics Development

Intracranial hemorrhage in a young COVID-328 19 patient

Anticoagulation use and Hemorrhagic Stroke in 330 SARS-CoV-2 Patients Treated at a New York Healthcare System

Angiotensin-converting enzyme 2 in the brain: properties and 333 future directions

Complement associated microvascular injury and 335 thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Renal histopathological analysis of 26 postmortem findings 338 of patients with COVID-19 in China

COVID-19: towards understanding of pathogenesis

Endothelial cell infection and endotheliitis in 342 COVID-19

Prognosis and Prevention of Non-346

Traumatic Intracerebral Hemorrhage

Coronavirus Disease 2019 and Stroke: Clinical 350 Manifestations and Pathophysiological Insights

Angiotensin-converting enzyme 2 353 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic 354 target

Immune Response, Inflammation, and the Clinical Spectrum of COVID-19

D-dimer level is associated with the severity of 358 COVID-19

D-dimer level in COVID-19 infection: a systematic 360 review

Plasma D-Dimer Concentrations and Risk of Intracerebral 362 Hemorrhage: A Systematic Review and Meta-Analysis

Intracerebral hemorrhage 364 outcome: A comprehensive update

Subarachnoid hemorrhage and COVID-19: 366 Association or coincidence?

Ruptured cerebral aneurysms in COVID-19 patients: 368 A review of literature with case examples

Long-term prognosis after intracerebral 370 haemorrhage: systematic review and meta-analysis

Older age is a strong predictor for poor outcome in 373 intracerebral haemorrhage: the INTERACT2 study

C-reactive protein in intracerebral hemorrhage: 375 time course, tissue localization, and prognosis